Hookipa Pharma (HOOK) Price & Analysis

Compare

542 Followers

HOOK Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.72 - $5.66

Previous CloseN/A

Volume38.61K

Average Volume (3M)118.13K

Market Cap

$11.22M

Enterprise Value-$26.23M

Total Cash (Recent Filing)$40.28M

Total Debt (Recent Filing)$596.00K

Price to Earnings (P/E)―

Beta2.19

Next Earnings

Aug 07, 2025

EPS Estimate

-0.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding9,799,053

10 Day Avg. Volume162,347

30 Day Avg. Volume118,128

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-2.34

Enterprise Value/Revenue-2.81

Enterprise Value/Gross Profit-3.03

Enterprise Value/Ebitda0.37

Forecast

1Y Price Target

$2.00

Price Target Upside138.10% Upside

Rating ConsensusHold

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Corporate RestructuringPoolbeg shareholders are expected to receive 0.03 shares of Hookipa for each Poolbeg share, resulting in approximately 55% of the equity of the combined entity.

Bears Say

Financial StabilityHookipa had approximately $60M in cash, which is believed to be insufficient to support the company to realize meaningful value inflection points from its own pipeline.

Shareholder DilutionHookipa plans to raise approximately $30M through a primary private placement, which is expected to lead to significant dilution for current Hookipa shareholders.

Hookipa Pharma News

Hookipa Pharma to delist shares from Nasdaq

Hookipa Pharma (HOOK) announced its intention to voluntarily delist from Nasdaq and to deregister its common stock. Published...

21d ago

HOOK

Hookipa Pharma Approves Asset Sale and Liquidation

An update from Hookipa Pharma ( ($HOOK) ) is now available. On July 29, 2025, HOOKIPA Pharma Inc....

10d ago

HOOK

Hookipa Pharma to Delist from Nasdaq Amid Asset Sale

The latest update is out from Hookipa Pharma ( ($HOOK) ). On July 18, 2025, HOOKIPA Pharma Inc....

21d ago

HOOK

Hookipa Pharma Sells Assets to Gilead Sciences

An announcement from Hookipa Pharma ( ($HOOK) ) is now available. On May 21, 2025, Hookipa Pharma and...

3M ago

HOOK

HOOK Earnings this Week: How Will it Perform?

Hookipa Pharma (HOOK) is scheduled to report 4th quarter earnings on 03/20/2025. Regarding Q4 estimates, Wall Street analysts...

5M ago

HOOK

Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial

HOOKIPA Pharma (HOOK) announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the...

6M ago

HOOK

Hookipa Pharma Seeks Validation for Stockholder Meetings

An update from Hookipa Pharma ( ($HOOK) ) is now available. HOOKIPA Pharma Inc. filed a petition in...

6M ago

HOOK

Hookipa Pharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Hookipa Pharma (HOOK) to Neutral from Buy without a price target after the company entered...

7M ago

HOOK

Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint

Check out this morning’s top movers from around Wall Street, compiled by The Fly. HIGHER – Topgolf Callaway...

7M ago

HCM

MCD

Hookipa Pharma to acquire Poolbeg Pharma

The boards of directors of Hookipa Pharma (HOOK) and Poolbeg Pharma announced that they have entered into non-binding...

7M ago

GILD

HOOK

Hookipa Pharma downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital downgraded Hookipa Pharma (HOOK) to Sector Perform from Outperform with a price target of $2, down...

8M ago

HOOK

Hookipa Pharma price target lowered to $7 from $24 at JMP Securities

JMP Securities lowered the firm’s price target on Hookipa Pharma (HOOK) to $7 from $24 and keeps an...

9M ago

HOOK

Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program

In a regulatory filing on Wednesday, Hookipa Pharma (HOOK) announced that on November 18, the company approved a...

9M ago

GILD

HOOK

Hookipa Pharma price target lowered to $48 from $50 at RBC Capital

RBC Capital lowered the firm’s price target on Hookipa Pharma (HOOK) to $48 from $50 and keeps an...

9M ago

HOOK

HOOK FAQ

What was Hookipa Pharma Inc’s price range in the past 12 months?

Hookipa Pharma Inc lowest stock price was $0.72 and its highest was $5.66 in the past 12 months.

What is Hookipa Pharma Inc’s market cap?

Hookipa Pharma Inc’s market cap is $11.22M.

When is Hookipa Pharma Inc’s upcoming earnings report date?

Hookipa Pharma Inc’s upcoming earnings report date is Aug 07, 2025 which is yesterday.

How were Hookipa Pharma Inc’s earnings last quarter?

Hookipa Pharma Inc released its earnings results on May 08, 2025. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.04 by -$0.19.

Is Hookipa Pharma Inc overvalued?

According to Wall Street analysts Hookipa Pharma Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hookipa Pharma Inc pay dividends?

Hookipa Pharma Inc does not currently pay dividends.

What is Hookipa Pharma Inc’s EPS estimate?

Hookipa Pharma Inc’s EPS estimate is -0.61.

How many shares outstanding does Hookipa Pharma Inc have?

Hookipa Pharma Inc has 9,799,053 shares outstanding.

What happened to Hookipa Pharma Inc’s price movement after its last earnings report?

Hookipa Pharma Inc reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.04. Following the earnings report the stock price went down -6.667%.

Which hedge fund is a major shareholder of Hookipa Pharma Inc?

Currently, no hedge funds are holding shares in HOOK

Company Description

Hookipa Pharma Inc

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Hookipa Pharma (HOOK) Earnings & Revenues

Historic Earnings Reports

HOOK Stock 12 Month Forecast

Average Price Target

$2.00

▲(138.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,1.3076923076923077,1.3653846153846154,1.4230769230769231,1.4807692307692308,1.5384615384615385,1.5961538461538463,1.6538461538461537,1.7115384615384617,1.7692307692307692,1.826923076923077,1.8846153846153846,1.9423076923076923,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,1.3076923076923077,1.3653846153846154,1.4230769230769231,1.4807692307692308,1.5384615384615385,1.5961538461538463,1.6538461538461537,1.7115384615384617,1.7692307692307692,1.826923076923077,1.8846153846153846,1.9423076923076923,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,1.3076923076923077,1.3653846153846154,1.4230769230769231,1.4807692307692308,1.5384615384615385,1.5961538461538463,1.6538461538461537,1.7115384615384617,1.7692307692307692,1.826923076923077,1.8846153846153846,1.9423076923076923,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.99,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.49,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >